Patents by Inventor Ravindra N. Guthikonda
Ravindra N. Guthikonda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7816534Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: GrantFiled: April 16, 2009Date of Patent: October 19, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: William K. Hagmann, Linus S. Lin, Shrenik K. Shah, Ravindra N. Guthikonda, Hongbo Qi, Linda L. Chang, Ping Liu, Helen M. Armstrong, James P. Jewell, Thomas J. Lanza, Jr.
-
Publication number: 20090258884Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: April 16, 2009Publication date: October 15, 2009Inventors: William K. Hagmann, Linus S. Lin, Shrenik K. Shah, Ravindra N. Guthikonda, Hongbo Qi, Linda L. Chang, Ping Liu, Helen M. Armstrong, James P. Jewell, Thomas J. Lanza, JR.
-
Patent number: 7550489Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: GrantFiled: February 1, 2008Date of Patent: June 23, 2009Assignee: Merck & Co., Inc.Inventors: William K. Hagmann, Linus S. Lin, Shrenik K. Shah, Ravindra N. Guthikonda, Hongbo Qi, Linda L. Chang, Ping Liu, Helen M. Armstrong, James P. Jewell, Thomas J. Lanza, Jr.
-
Publication number: 20080171692Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: February 1, 2008Publication date: July 17, 2008Inventors: William K. Hagmann, Linus S. Lin, Shrenik K. Shah, Ravindra N. Guthikonda, Hongbo Qi, Linda L. Chang, Ping Liu, Helen M. Armstrong, James P. Jewell, Thomas J. Lanza
-
Patent number: 6972295Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: GrantFiled: March 12, 2003Date of Patent: December 6, 2005Assignee: Merck & Co., Inc.Inventors: William K. Hagmann, Linus S. Lin, Shrenik K. Shah, Ravindra N. Guthikonda, Hongbo Qi, Linda L. Chang, Ping Liu, Helen M. Armstrong, James P. Jewell, Thomas J. Lanza, Jr.
-
Publication number: 20040058820Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.Type: ApplicationFiled: March 12, 2003Publication date: March 25, 2004Inventors: William K. Hagmann, Linus S. Lin, Shrenik K. Shah, Ravindra N. Guthikonda, Hongbo Qi, Linda L. Chang, Ping Liu, Helen M. Armstrong, James P. Jewell, Thomas J. Lanza
-
Patent number: 6248755Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.Type: GrantFiled: April 4, 2000Date of Patent: June 19, 2001Assignee: Merck & Co., Inc.Inventors: Kevin Chapman, Jeffrey Hale, Dooseop Kim, Christopher Lynch, Shrenik Shah, Kothandaraman Shankaran, Dong-Ming Shen, Christopher Willoughby, Malcolm MacCoss, Sander G. Mills, Jennifer L. Loebach, Ravindra N. Guthikonda
-
Patent number: 5629322Abstract: Disclosed herein are compounds of Formula I ##STR1## and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis.Type: GrantFiled: June 6, 1995Date of Patent: May 13, 1997Assignee: Merck & Co., Inc.Inventors: Ravindra N. Guthikonda, Stephan K. Grant, Malcolm Maccoss, Shrenik K. Shah, Kothandaraman Shankaran, Charles G. Caldwell, Philippe L. Durette
-
Patent number: 5532261Abstract: Compounds are disclosed represented by the formula: ##STR1## wherein Y is: ##STR2## or a pharmaceutically acceptable salt or ester thereof. ##STR3## represents an aromatic 6 membered ring; zero or one of T, U, V and W represents N.sup.+ R.sup.y and the remainder of T, U, V and W are independently selected from C and N, such that one of T, U, V and W represents N.sup.+ R.sup.y or N.Pharmaceutical compositions and methods of use are also included.Type: GrantFiled: December 12, 1994Date of Patent: July 2, 1996Assignee: Merck & Co., Inc.Inventors: Frank P. DiNinno, Ravindra N. Guthikonda, Laura C. Meurer
-
Patent number: 5409920Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.Type: GrantFiled: October 5, 1990Date of Patent: April 25, 1995Assignee: Merck & Co., Inc.Inventors: Ravindra N. Guthikonda, Frank P. DiNinno
-
Patent number: 5342933Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.Type: GrantFiled: August 28, 1992Date of Patent: August 30, 1994Assignee: Merck & Co., Inc.Inventors: Frank DiNinno, Susan M. Schmitt, Ravindra N. Guthikonda
-
Patent number: 5334590Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.Type: GrantFiled: July 16, 1993Date of Patent: August 2, 1994Assignee: Merck & Co., Inc.Inventors: Frank DiNinno, Ravindra N. Guthikonda
-
Patent number: 5294610Abstract: Carbapenems of the formula ##STR1## wherein a suitably substituted aza-9-fluorenone is attached at the 2-position of the carbapenem are useful antibacterial agents.Type: GrantFiled: October 15, 1992Date of Patent: March 15, 1994Assignee: Merck & Co. Inc.Inventors: Frank P. DiNinno, Ravindra N. Guthikonda
-
Patent number: 5292879Abstract: Carbapenem compounds of the formula ##STR1## are useful intermediates for preparing antibacterial agents.Type: GrantFiled: August 28, 1992Date of Patent: March 8, 1994Assignee: Merck & Co., Inc.Inventors: Frank DiNinno, Ravindra N. Guthikonda, Susan M. Schmitt
-
Patent number: 5256777Abstract: Carbapenems of the formula ##STR1## are useful intermediates to antibacterial agents.Type: GrantFiled: October 17, 1991Date of Patent: October 26, 1993Assignee: Merck & Co., Inc.Inventors: Frank DiNinno, Ravindra N. Guthikonda
-
Patent number: 5220011Abstract: Carbapenem intermediates of the formula ##STR1## where: M is a removable protecting group for carboxy, andP' is a removable protecting group for hydroxyare useful intermediates for preparing antibacterial agents.Type: GrantFiled: June 25, 1991Date of Patent: June 15, 1993Assignee: Merck & Co., Inc.Inventors: Frank P. DiNinno, Ravindra N. Guthikonda, Susan M. Schmitt
-
Patent number: 5143914Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.Type: GrantFiled: June 25, 1991Date of Patent: September 1, 1992Assignee: Merck & Co., Inc.Inventors: Frank P. DiNinno, Ravindra N. Guthikonda, Susan M. Schmitt
-
Patent number: 5138050Abstract: New antibacterial 6-amido-1-methylcarbapenems and process for their synthesis involving new azetidinone intermediates.Type: GrantFiled: March 7, 1991Date of Patent: August 11, 1992Assignee: Merck & Co., Inc.Inventors: Ravindra N. Guthikonda, Frank P. DiNinno, Thomas N. Salzmann
-
Patent number: 5128335Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.Type: GrantFiled: October 15, 1990Date of Patent: July 7, 1992Assignee: Merck & Co., Inc.Inventors: Ravindra N. Guthikonda, Susan M. Schmitt, Frank P. Dininno
-
Patent number: 4298741Abstract: Disclosed are 6-amido-3-substituted-1-azabicyclo[3.2.0]hept-2-en-7-one-2-carboxylic acids (I): ##STR1## wherein R.sup.1 is hydrogen or acyl; andX is halo, oxygen (the 2-3 bond is saturated and the species I exists as a carboxylate salt or ester), or --OR wherein R is, inter alia, acyl, alkyl, or aralkyl. Such compounds and their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.Type: GrantFiled: July 11, 1980Date of Patent: November 3, 1981Assignee: Merck & Co., Inc.Inventors: Burton G. Christensen, Ravindra N. Guthikonda, Ronald W. Ratcliffe